Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

29. August 2018 16:05 ET | Quelle: Paratek Pharmaceuticals

Paratek Pharmaceuticals to Present at Baird's 2018 Global Healthcare Conference

BOSTON, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that it will present at Baird's 2018 Global Healthcare Conference on Wednesday, September 5 at...
08. August 2018 14:20 ET | Quelle: Paratek Pharmaceuticals

FDA Advisory Committee Recommends Approval of Paratek’s Omadacycline

-- Positive vote for both the skin infections and pneumonia indications -- -- FDA decision expected in early October 2018 -- BOSTON, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc....
08. August 2018 07:05 ET | Quelle: Paratek Pharmaceuticals

Paratek Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Omadacycline New Drug Applications for the Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections

BOSTON, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
02. August 2018 16:01 ET | Quelle: Paratek Pharmaceuticals

Paratek Pharmaceuticals Reports Second Quarter 2018 Financial Results

-- Antimicrobial Drugs Advisory Committee of FDA scheduled for August 8, 2018 to review the Company's NDAs for omadacycline -- -- Omadacycline PDUFA action date scheduled for October 2018 -- --...
23. Juli 2018 07:30 ET | Quelle: Paratek Pharmaceuticals

Paratek Pharmaceuticals to Report Second Quarter 2018 Financial Results on August 2, 2018

BOSTON, July 23, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
20. Juni 2018 09:05 ET | Quelle: Paratek Pharmaceuticals

Paratek Announces FDA Advisory Committee Date for Omadacycline

BOSTON, June 20, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
11. Juni 2018 08:00 ET | Quelle: Paratek Pharmaceuticals

Paratek Presents New Analysis from Combined Phase 3 Skin Infection Studies Highlighting Efficacy of Omadacycline in Treating Drug Resistant S. aureus at ASM Microbe 2018

BOSTON, June 11, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
07. Juni 2018 16:05 ET | Quelle: Paratek Pharmaceuticals

Paratek Demonstrates Breadth of Omadacycline Clinical and Microbiological Data at ASM Microbe 2018

Poster presentations will include new analysis of efficacy against drug resistant S. aureus in skin infections BOSTON, June 07, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc....
01. Juni 2018 16:30 ET | Quelle: Paratek Pharmaceuticals

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

BOSTON, June 01, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
22. Mai 2018 16:01 ET | Quelle: Paratek Pharmaceuticals

Paratek Presents New Analysis Highlighting Efficacy of Omadacycline in Treating Community-Acquired Bacterial Pneumonia by Measures of Disease Severity

Data Presented During “New Insights in Acute Pulmonary Infections” Oral Session at American Thoracic Society 2018 International Conference BOSTON, May 22, 2018 (GLOBE NEWSWIRE) -- Paratek...

Vorherige Seite

Nächste Seite